Liminatus Pharma Signs MOU With Capital Trust Group For $30M Equity Financing Via Earn-Out Mechanism To Support Liminatus's R&D Of Advanced Immunotherapy Assets

Author: Benzinga Newsdesk | October 27, 2025 12:38pm

Liminatus Pharma, Inc. (NASDAQ:LIMN), La Palma, CA, a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today that it has entered into a Memorandum of Understanding (MOU) with Capital Trust Group Limited (CTG), a New Zealand-based investment management firm, for a USD 30,000,000 equity financing via an earn-out mechanism to support Liminatus's research and development of advanced immunotherapy assets.

Subject to completion of diligence and the negotiation of definitive agreements, CTG intends to subscribe to newly issued shares of Liminatus, subject to compliance with Nasdaq listing rules and U.S. securities laws. The subscription funds are expected to be remitted following the submission and effectiveness of a registration statement relating to the resale of the shares. Both parties aim to finalize and execute the definitive agreements in November 2025.

In addition to the equity investment, beginning in mid-November this year and subject to definitive agreements being signed, Liminatus and CTG plan to commence discussions for further strategic cooperation, including potential future digital bond financing programs.

Posted In: LIMN